TILDRAKIZUMAB, A SELECTIVE IL-23P19 ANTIBODY, IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: RESULTS FROM TWO RANDOMIZED, CONTROLLED, PHASE 3 TRIALS

被引：0
|
作者：
Sinclair, R. [1 ]
Reich, K. [2 ,3 ]
Papp, K. [4 ]
Blauvelt, A. [5 ]
Tyring, S. [6 ]
Thaci, D. [7 ]
Cichanowitz, N. [8 ]
Mehta, A. [8 ]
Li, Q. [8 ]
Liu, K. [8 ]
La Rosa, C. [8 ]
Green, S. [8 ]
Kimball, A. [9 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] Sciderm Res Inst, Hamburg, Germany
[3] Dermatologikum Hamburg, Hamburg, Germany
[4] Prob Med Res, Waterloo, ON, Canada
[5] Oregon Med Res Ctr, Tigard, OR USA
[6] Univ Texas, Austin, TX USA
[7] Univ Lubeck, Lubeck, Germany
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Harvard Med Sch, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2017年 / 56卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
0177
引用
收藏
页码：1238 / 1239
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
    Sofen, Howard L.
    Gebauer, Kurt
    Spelman, Lynda
    Yamauchi, Paul S.
    Yao, Siu-Long
    Nishandar, Tushar
    Kopeloff, Iris
    Crane, Michael
    Gogineni, Ranga
    Kothekar, Mudgal
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (04) : 816 - 824
  • [42] Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
    Bussel, James
    Arnold, Donald M.
    Grossbard, Elliot
    Mayer, Jiri
    Trelinski, Jacek
    Homenda, Wojciech
    Hellmann, Andrzej
    Windyga, Jerzy
    Sivcheva, Liliya
    Khalafallah, Alhossain A.
    Zaja, Francesco
    Cooper, Nichola
    Markovtsov, Vadim
    Zayed, Hany
    Duliege, Anne-Marie
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 921 - 930
  • [43] Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
    Michael Sticherling
    Arjen F. Nikkels
    Ashraf M. Hamza
    Pearl Kwong
    Jacek C. Szepietowski
    Mahira El Sayed
    Pierre-Dominique Ghislain
    Alkes A. Khotko
    Manmath Patekar
    Christine-Elke Ortmann
    Pascal Forrer
    Philemon Papanastasiou
    Deborah Keefe
    American Journal of Clinical Dermatology, 2023, 24 : 821 - 835
  • [44] Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
    Sticherling, Michael
    Nikkels, Arjen F.
    Hamza, Ashraf M.
    Kwong, Pearl
    Szepietowski, Jacek C.
    El Sayed, Mahira
    Ghislain, Pierre-Dominique
    Khotko, Alkes A.
    Patekar, Manmath
    Ortmann, Christine-Elke
    Forrer, Pascal
    Papanastasiou, Philemon
    Keefe, Deborah
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 821 - 835
  • [45] Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis
    Khalilieh, Sauzanne
    Hussain, Azher
    Montgomery, Diana
    Levine, Vanessa
    Shaw, Peter M.
    Bodrug, Inga
    Mekokishvili, Lally
    Bailey-Smith, Candice
    Glasgow, Xiaoli S.
    Cheng, Amy
    Martinho, Monika
    Iwamoto, Marian
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (10) : 2292 - 2302
  • [46] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [47] Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
    Papp, Kim
    Menter, Alan
    Sofen, Howard
    Tyring, Stephen
    Lacour, Jean-Philippe
    Berner, Beate
    Bennett, Nathan
    Aslanyan, Stella
    Flack, Mary
    Scholl, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [48] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
  • [49] Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
    Bai, Fan
    Li, Gang Gang
    Liu, Qingmin
    Niu, Xinwu
    Li, Ruilian
    Ma, Huiqun
    JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
  • [50] Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial
    Abe, Masatoshi
    Nishigori, Chikako
    Torii, Hideshi
    Ihn, Hironobu
    Ito, Kei
    Nagaoka, Makoto
    Isogawa, Naoki
    Kawaguchi, Isao
    Tomochika, Yukiko
    Kobayashi, Mihoko
    Tallman, Anna M.
    Papp, Kim A.
    JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1228 - 1237
12345